Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) reported Q2 EPS of ($0.29), $0.04 worse than the analyst estimate of ($0.25).

For earnings history and earnings-related data on Rigel Pharmaceuticals, Inc. (RIGL) click here.